Fig. 1 · Structure

Documents & Downloads

Orotic acid (6-Carboxyuracil)

Cat. No. A10677 CAS 65-86-1
Orotic acid(6-Carboxyuracil) is a heterocyclic compound and an acid.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 EC50 1 mM Substrate uptake by the Glucose Transporter Type 9 (GLUT9, SLC2A9) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 cells stably transfected with SLC2A9 isoform 1 10.5281/zenodo.7360607
HEK293 EC50 1 mM Substrate uptake by the Glucose Transporter Type 9 (GLUT9, SLC2A9) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 cells stably transfected with SLC2A9 isoform 2 10.5281/zenodo.7360607

Orotic acid (6-Carboxyuracil) Research Summary

This section summarizes 2 in vitro studies of Orotic acid (6-Carboxyuracil) from 2 published references. In vitro models include SH-SY5Y cell line; C. trachomatis strain GO/86, serotype D.

Orotic acid (6-Carboxyuracil) In Vitro Studies

Orotic acid metabolite assemblies were evaluated in cultured SH-SY5Y cells using an XTT viability assay. At the highest tested concentration, cell viability decreased to about 50%. In C. trachomatis strain GO/86, serotype D, treatment with Orotic acid produced no significant reduction in infectivity, assessed by direct immunofluorescence counting of Chlamydia IFU. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell Viability Following Metabolite Assembly Exposure

Cell-based study · SH-SY5Y cell line [1]

Cultured SH-SY5Y cells were exposed to Orotic acid metabolite assemblies, and viability was assessed using an XTT assay. At the highest tested concentration, cell viability decreased to about 50%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
XTT cell viability assaycell viability Orotic acid; metabolite assemblies; 2 mg/ml; 6 hours at 37°C: cell viability to about 50%[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.2 mg/ml, 2 mg/ml, 1 mg/ml
Exposure duration
6 hours at 37°C
Method
added to the cultured SH-SY5Y cell line
Vehicle
DMEM/Nutrient Mixture F12 (Ham’s) (1:1)
Methods and source locations

Compound reported in the paper: Orotic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS (S23, S24, S25, S30); MATERIALS AND METHODS > Cell cytotoxicity experiments (S71, S75, S76); Fig. 3 legend (S115, S116, S121)

XTT cell viability assay: XTT cell viability assay; comparator: medium with no metabolites, which was treated in the same manner — RESULTS (S23, S25, S30); MATERIALS AND METHODS > Cell cytotoxicity experiments (S75); Fig. 3 legend (S115, S121)

Chlamydia infectivity following treatment

Cell-based study · C. trachomatis strain GO/86, serotype D [2]

C. trachomatis strain GO/86, serotype D, was treated with Orotic acid at 30 μM. No significant reduction in infectivity was observed by counting Chlamydia IFU using direct immunofluorescence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
counting Chlamydia IFU by direct immunofluorescenceReported result no significant reduction of C. trachomatis infectivity was observed[2]

Literature-Reported Treatment Conditions

Treatment concentration
30 μM
Exposure duration
7, 15 and 60 minutes
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Orotic acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Identification of Lactobacillus metabolic profiles associated with anti-Chlamydia activity (S71); Methods > C. trachomatis propagation and preparation of EBs (S88); Methods > C. trachomatis inhibition test (S98, S99, S102, S105)

counting Chlamydia IFU by direct immunofluorescence: counting Chlamydia IFU by direct immunofluorescence; comparator: The same amount of purified EBs was used as control — Results > Identification of Lactobacillus metabolic profiles associated with anti-Chlamydia activity (S71); Methods > C. trachomatis inhibition test (S105)

Specifications

Manufacturer Adooq Bioscience
CAS Number 65-86-1
Formula C5H4N2O4
Molecular Weight 156.1
Synonyms 6-Carboxyuracil; Orodin; Oropur; Orotonin; Orotonsan
SMILES
C1=C(NC(=O)NC1=O)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 2 mg/mL (12.81 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Orotic acid (6-Carboxyuracil) Research References

  1. [1] Shaham-Niv S, Adler-Abramovich L, Schnaider L, et al. Extension of the generic amyloid hypothesis to nonproteinaceous metabolite assemblies. Sci Adv (2015). PMID: 26601224 DOI: 10.1126/sciadv.1500137 Source material
  2. [2] Nardini P, Ñahui Palomino RA, Parolin C, et al. Lactobacillus crispatus inhibits the infectivity of Chlamydia trachomatis elementary bodies, in vitro study. Sci Rep (2016). PMID: 27354249 DOI: 10.1038/srep29024 Source material

Added to your cart

View Cart Checkout
Loading...